September 5, 2017 / 12:12 PM / 2 months ago

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

Sept 5 (Reuters) - Minerva Neurosciences Inc

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

* Approximately 280 patients are planned to be enrolled at more than 85 clinical sites in U.S., Europe, Russia and Japan​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below